MedTrace Logo

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly

NCT00938392 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 726

Last updated 2018-08-20

Study results available
· View outcomes & findings →

Summary

The objective of the study is to evaluate immunogenicity between different formulations of GSK Biologicals' investigational vaccine GSK2186877A.

Conditions

Interventions

BIOLOGICAL

GSK investigational FluNG vaccine GSK2186877A, aged lot

Single dose, intramuscular injection

BIOLOGICAL

GSK investigational FluNG vaccine GSK2186877A, fresh lot

Single dose, intramuscular injection

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-30
Primary Completion
2009-10-05
Completion
2009-10-05

Countries

  • Estonia
  • Slovakia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00938392 on ClinicalTrials.gov